Company

Edgewise Therapeutics, Inc.

Headquarters: Boulder, CO, United States

Employees: 31

CEO: Dr. Kevin Koch Ph.D.

NASDAQ: EWTX -5.46%

Market Cap

$3.09 Billion

USD as of Jan. 1, 2025

Market Cap History

Edgewise Therapeutics, Inc. market capitalization over time

Evolution of Edgewise Therapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Edgewise Therapeutics, Inc.

Detailed Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date Sept. 30, 2024
Revenue TTM $0
EBITDA $-145,179,008
Gross Profit TTM $0
Profit Margin 0.00%
Operating Margin 0.00%
Quarterly Revenue Growth %
Financial Reports & Statistics

Stocks & Indices

Edgewise Therapeutics, Inc. has the following listings and related stock indices.


Stock: NASDAQ: EWTX wb_incandescent

Details

Headquarters:

3415 Colorado Avenue

Boulder, CO 80303

United States

Phone: 303 735 8373